Top Markets
#1 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +585.95%
#2 Phala Phala +86.06%
#3 Bitway Bitway +35.59%
#4 龙虾 (Lobster) 龙虾 (Lobster) +27.08%
#5 Backpack Backpack +25.83%
#6 ARK ARK +24.61%
#7 Mubarak Mubarak +24.07%
#8 Aerodrome Finance Aerodrome Finance +23.48%
#9 APEX APEX +21.77%
#10 The Black Bull The Black Bull +20.57%
Coin of the day
Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain)
Ρυθμίσεις
Γλώσσα
Ελληνικά
Νόμισμα
USD
Θέμα
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Κατάταξη σε μετοχές #36735
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to... Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Τιμή μετοχής
$0.2483
Τελευταίος συγχρονισμός: 2026-07-31
Κεφαλαιοποίηση
$2.30M
Αλλαγή (1 ημέρα)
-3.39%
Αλλαγή (1 έτος)
-89.01%
Χώρα
US
Εμπόριο Ensysce Biosciences, Inc. (ENSC)

Κατηγορία

Healthcare
Κέρδη για την Ensysce Biosciences, Inc. (ENSC)
Κέρδη τον Jun 2026 TTM: $-12.62M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Ensysce Biosciences, Inc., τα τρέχοντα κέρδη της εταιρείας είναι $-12.62M. Το 2023, η εταιρεία παρουσίασε κέρδη $-10.63M, αύξηση σε σχέση με των κερδών του 2022 που ήταν $-24.21M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Ensysce Biosciences, Inc. από 2017 έως 2026
Κέρδη στο τέλος κάθε έτους
Έτος Κέρδη Αλλαγή
2026 (TTM) $-12.62M 58.06%
2024 $-7.99M -24.84%
2023 $-10.63M -56.10%
2022 $-24.21M -16.94%
2021 $-29.15M 18,017.11%
2020 $-160.88K -98.41%
2019 $-10.10M -477.51%
2018 $2.68M -9,810.43%
2017 $-27.56K 0.00%
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
Εταιρεία Κέρδη Διαφορά Κερδών Χώρα
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -41,883.41%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 24,352.67%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -15,551.44%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 31,713.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH